Minimed announces launch of IPO roadshow

Minimed announces launch of IPO roadshow

MiniMed Announces Launch of IPO Roadshow Amid Strategic Separation from Medtronic
February 24, 2026

MiniMed Group, the diabetes business of Medtronic plc (NYSE: MDT), has commenced its initial public offering (IPO) roadshow following the filing of its registration statement with the U.S. Securities and Exchange Commission (SEC) in December 2025. The company intends to list its shares on the Nasdaq Global Select Market under the ticker symbol "MMED" according to company announcements.

The IPO follows Medtronic's previously announced plan to separate its diabetes division into an independent, publicly traded entity. The process involves a series of capital markets transactions, with an IPO and subsequent split-off as the preferred structure. While the number of shares and pricing range remain undetermined, the offering is subject to SEC approval and market conditions.

Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley are leading the underwriting effort, supported by additional joint bookrunners including Barclays and Deutsche Bank. The roadshow, typically used to gauge investor demand, aligns with broader market activity as companies prepare for a potential IPO market rebound in early 2026 amid seasonal slowdowns.

MiniMed's business focuses on advanced diabetes management technologies, including continuous glucose monitoring (CGM) systems, insulin delivery devices, and data-driven solutions. As a standalone entity, it aims to accelerate innovation in diabetes care while maintaining its position as a leader in the $25 billion global diabetes technology market.

Medtronic emphasized that the separation is intended to be tax-efficient and will not immediately impact its core operations. However, forward-looking statements regarding the IPO's timing, pricing, and success are subject to risks, including regulatory delays, market volatility, and operational challenges inherent in spin-offs.

Investors are advised to review the preliminary prospectus, available through lead underwriters, for detailed financial and strategic disclosures. The IPO marks a significant step in Medtronic's corporate strategy to streamline its portfolio while empowering MiniMed to pursue independent growth in the evolving healthcare landscape.

(https://news.medtronic.com/2025-12-19-Medtronic-announces-filing-of-IPO-registration-statement-for-Diabetes-business,-MiniMed): Medtronic plc, December 19, 2025 press release.
(https://www.reuters.com/business/healthcare-pharmaceuticals/medtronics-minimed-files-us-ipo-2025-12-19/): Reuters, December 19, 2025.